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Intellectual disability (ID) is a neurodevelopmental disorder characterized by limitations in
both intellectual and behavioral functioning. It can occur in non-syndromic and syn-
dromic forms involving multiple organs. While the majority of genetic variants linked to
ID are de novo, inherited variants are also detected in some forms. Here, we report a
consanguineous Lebanese family presenting with an autosomal recessive syndromic ID
characterized by neurodevelopmental delay, mild dysmorphic features, hearing impair-
ment and endocrine dysfunction. Whole exome sequencing enabled the detection of the
homozygous nonsense mutation in BOD1, p.R151X, in the proband. BOD1 is required
for chromosomes biorientation during cell division. It also contributes to the regulation
of cell survival and to the modulation of fatty acid metabolism. Another nonsense muta-
tion in BOD1 was linked to ID in a consanguineous Iranian family. This is the second
report of BOD1 mutations in humans and the first in a syndromic ID including gonadal
dysfunction and high-frequency hearing impairment. Our findings confirm the involve-
ment of BOD1 in cognitive functioning and expand the clinical spectrum of BOD1
deficiency.
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1 | BACKGROUND
Intellectual disability (ID) is a neurodevelopmental disorder characterized
by limitations in intellectual functioning assessed by the Intelligence
Quotient (IQ) and in adaptive behaviors.1 It affects 1 to 3% of the general
population.2 Mild, moderate, severe, and profound are terms commonly
used to define the severity of the disease.3 In parallel, ID disorders
are grouped into non-syndromic or syndromic ID where patients show
additional clinical signs such as dysmorphic features, skeletal and/or
metabolic defects.4 While environmental factors can lead to
non-syndromic ID,5,6 a genetic etiology is thought to be present in 15%
to 62% of ID cases,7,8 especially in severe forms.9 The majority of genetic
variants linked to severe ID are de novo.7,8,10 However, inherited
variants are also detected in autosomal dominant and recessive ID
disorders.11,12 Chromosomal aberrations and copy number variations
account for about 15% of ID cases.7,8 Pathogenic SNVs (Single
Nucleotide Variations), occurring in coding genomic regions are
responsible for more than 50% of ID cases. Pathogenic non-coding
SNVs regulating gene expression may also lead to ID.7,8 Therefore,
diagnostic yield of whole genome sequencing in patients with ID can
reach 62%.8 Nevertheless, the molecular basis of several ID disor-
ders remains unelucidated.
Here we report a homozygous nonsense mutation in BOD1 in a
consanguineous Lebanese family presenting a syndromic form of
Abbreviations: AAIDD, American Association on Intellectual and Developmental Disabilities;
CADD, combined annotation dependent depletion; DSM, diagnostic and statistical manual of
mental disorders; ExAC, exome aggregation consortium; ID, intellectual disability; IQ,
intelligence quotient; MAF, minor allele frequency; OFC, occipital head circumference; SD,
standard deviation; SNV, single nucleotide variation; WES, whole exome sequencing.
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ID. This is the second report of BOD1 mutations in humans and the
first in syndromic ID including gonadal dysfunction and high-
frequency hearing impairment.
2 | MATERIAL AND METHODS
2.1 | Patients
A 14-year-old affected boy, born to a consanguineous Lebanese fam-
ily is reported in this study. A history of two miscarriages existed in
the family. Pregnancy and delivery were normal. Physical examination
at birth demonstrated normal weight, height and occipital head cir-
cumference (OFC). There was no history of postnatal infection or
trauma. Severe myopia and signs of psychomotor delay started to
show on the patient at 1 year of age.
At the age of 9 years, he was diagnosed with syndromic ID
including short stature (−2 SD), mild dysmorphic features, high-
frequency hearing impairment (Figure 1), obesity, endocrine dysfunc-
tion and micropenis with cryptorchidism. Dysmorphic features
included: microcephaly (OFC = 52 cm, 35th centile), strabismus, ear
lobes deformities, short neck, small hands (13 cm, <3rd centile) and
small feet. The neurodevelopmental delay in the patient consisted in
limitations in both behavioral and intellectual functioning (with an IQ
of 44), speech delay, attention deficit and learning difficulties. Endo-
crine dysfunction was mainly defined by Hypogonadotropic hyp-
ogonadism and short stature including 20 months of bone age delay.
Brain magnetic resonance imaging, electroencephalography and thy-
roid function evaluation were normal.
Parents also reported that the proband has an uncle presenting
ID, dysmorphic features, short stature, plethoric obesity, small hands,
ear malformations as well as attention deficit, learning difficulties and
hypogonadism. However, further evaluation of this patient was not
possible because he refused to participate in this study.
2.2 | Isolation of genomic DNA
Written informed consent was obtained from the parents for study
enrollment and publication. DNA was extracted from peripheral blood
by standard methods.13
2.3 | Whole exome sequencing (WES)
Sequences were captured and enriched using Agilent SureSelect
Human All Exon kit version 5.0. Samples were then multiplexed and
sequenced on an Illumina HiSeq 2500 PE100-125. FASTQ files were
aligned to the hg19/b37 reference genome using the Burrows-
Wheeler Aligner (BWA) package version v0.6.1.14 Variant calling was
performed using the Genome Analysis Tool Kit (GATK)15 version 3.3,
then annotated with VarAFT 1.61.17Variants were filtered for
protein-altering variants, including truncating variants, canonical
splice-site variants and missense variants, based on their frequency
in dbSNPv137 (<1%), ExAC/gnomAD v2.11 (<1%) and our in-house
database (<1%).
2.4 | Sanger sequencing
Selected variants were studied in the proband, his parents and two of
his unaffected siblings by Sanger sequencing.
F IGURE 1 Audiograms showing high-frequency hearing impairment in the proband [Colour figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
WES was performed on the proband DNA. Data was first filtered
for rare protein-altering variants including canonical splice-site
variants. Then, assuming an autosomal recessive condition occur-
ring in a consanguineous family, we selected homozygous vari-
ants. This led to the identification of 17 variants in different
genes (Table 1) of which six are associated with diseases in
human. Among these, NCAPG2 and BOD1 were selected as candi-
date based on the clinical manifestation of the patient. Sanger
sequencing allowed the exclusion of the NCAPG2 variant that
was homozygous in one of the unaffected sibling and the selec-
tion of the nonsense mutation in BOD1 (NM_138369: c.451C>T;
p.R151*) that segregated with the disease in the family
(Figure 2). This variant is absent in our local database, found at
very low frequency at a heterozygous state in ExAC (minor
allele frequency of 0.0000159) and has a CADD (Combined
Annotation Dependent Depletion) score of 39, suggesting that it
is pathogenic.
In parallel, heterozygous variants in genes known to be linked to
autosomal dominant neurodevelopmental disorders were ruled out by
a targeted analysis of WES data.
4 | DISCUSSION
Here, we report a homozygous nonsense mutation in BOD1 in a con-
sanguineous Lebanese patient with a syndromic form of ID, including
gonadal dysfunction and high-frequency hearing impairment. BOD1
(Biorientation of chromosomes in cell division 1) is required for chromo-
somes biorientation during cell division.16 It is localized at kinetochores
from prometaphase until anaphase16 where it inhibits the phosphatase
2A, thus regulating cell cycle progression.17,18 A homozygous nonsense
mutation in BOD1 (NM_138369: c.334C>T; p.R112*) was previously
observed in four female siblings of a consanguineous Iranian family, suf-
fering from mild to moderate ID. Reported patients also presented pri-
mary or secondary amenorrhea of unknown cause occurring in the
absence of endocrine dysregulation.19 The identification of a novel
nonsense mutation in BOD1 in the family reported herein expands the
clinical spectrum of BOD1 deficiency and links the gene to a syndromic
ID including a gonadal dysfunction, dysmorphic features and moderate
hearing impairment. Further to the involvement of BOD1 in cell cycle
regulation, this protein plays an important role in post mitotic neurons
where it contributes to the development and maintenance of cognitive
features.19 It also modulates fatty acid metabolism that is mediated
by its interaction with the histone lysine methyltransferase SET1B.
TABLE 1 List of the homozygous identified variants by WES analysis
Gene






EME2 NA NM_001257370.1 c.7C>T (p.Arg3Trp) 23.9 - Uncertain Significance
MYOM3 NA NM_152372.4 c.3934G>C (p.Ala1312Pro) 33 - Uncertain Significance
ZNF638 NA NM_001014972.2 c.1538A>G (p.His513Arg) 0.012 0.0003 Likely Benign
DOK5 NA NM_018431.5 c.353A>G (p.Asp118Gly) 23.1 0.0001 Uncertain Significance
CEP55 Hydranencephaly with
renal aplasia-dysplasia
NM_001127182.2 c.641A>G (p.His214Arg) 10.07 0.0001 Likely Benign
XYLT2 Spondyloocular
syndrome
NM_022167.4 c.128C>A (p.Ala43Glu) 23.1 Likely Benign
NCAPG2 Khan-Khan-Katsanis
syndrome
NM_017760.7 c.2456C>T (p.Pro819Leu) 13.3 9.70E−05 Likely Benign
BOD1 Intellectual disability NM_138369.3 c.451C>T (p.Arg151Ter) 39 - Uncertain Significance
MKI67 NA NM_002417.5 c.8042G>A (p.Gly2681Asp) 21.5 - Likely Benign
SATL1 NA NM_001012980.2 c.1750G>A (p.Val584Ile) 16.46 - Uncertain Significance





NM_003291.4 c.1270A>G (p.Ile424Val) 10.38 6.46E−05 Likely Benign
PHPT1 NA NM_001287343.2 c.331A>G (p.Ile111Val) 2.165 - Likely Benign
C2CD6 NA NM_001168221.2 c.4783C>T (p.Gln1595Ter) 37 - Uncertain Significance
RPS11 NA NM_001015.5 c.39G>C (p.Gln13His) 27.6 - Uncertain Significance
MMEL1 NA NM_033467.4 c.1366G>A(p.Val456Ile) 19.62 0.0002 Likely Benign
ANTXR1 GAPO syndrome NM_032208.2 c.1312C>T (p.Arg438Cys) 32 0.0003 Uncertain Significance
Abbreviations: CADD, combined annotation dependent depletion; MAF, minor allele frequency; NA, not available.
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Indeed, BOD1 is a cytoplasmic-specific subunit of COMPASS, a com-
plex of proteins associated with Set1.20 Interestingly, de novo mutations
in SETD1B encoding SET1B, are associated with syndromic ID, epilepsy
and autism.21 Given that BOD1 stabilizes SET1B and is essential for its
activity,20 we propose that the cognitive impairment associated with
BOD1 deficiency might be mediated by SET1B. In parallel, loss of SET1B
or BOD1 induces the upregulation of adiponectin receptor 1 (AdipoR1)
and activation of its signaling pathway.20 Adiponectin, an adipose tissue-
derived hormone, links the regulation of metabolic homeostasis with
reproductive processes.22 AdipoR1 is expressed in hypothalamic-pituitary-
gonadal axis and its activation regulates the expression and/or secretion
of Kiss, gonadotropin-releasing hormone and gonadotropin. Adiponectin
plays essential roles in fertility; from gametogenesis to gestation. It also
contributes to embryo development.23 This suggests that the modulation
of adiponectin signaling pathways by BOD1 deficiency might be responsi-
ble for the gonadal disorder of our patients and for the amenorrhea in the
reported Iranian family.19
Last but not least, while complete loss of Bod1 in mice is lethal,
heterozygous carriers of the Bod1 knock-out allele show hearing
impairment at high frequencies.24 This phenotype is interestingly
observed in the proband and not seen in any of his unaffected sib-
lings, thus suggesting its possible link with BOD1 deficiency.
Unfortunately, hearing performance was not assessed in the
Iranian family.19 Reporting further cases with BOD1 deficiency is
crucial to better delineate the spectrum of this disease.
Here, we report a novel homozygous nonsense mutation in
BOD1 in a consanguineous Lebanese patient with ID syndromic
form. This is the second report of BOD1 mutations in humans and
the first associated with syndromic ID including gonadal dysfunc-
tion and high-frequency hearing impairment. Our findings confirm
the involvement of BOD1 in cognitive development and expand
the clinical spectrum of the disease linked to a mutation in this
gene. Further functional studies in murine models are also essential
for the elucidation of the pathogenic mechanisms of BOD1
deficiency.
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